05. April 2017

Abstract Local delivery of drugs and biopharmaceuticals for the treatment of inflammatory bowel disease remains a challenge. Innovative nanomedicines with appropriate properties raise the possibility of efficient drug targeting. Hence, the overall aim of this study was to develop and characterize a protamine-based nanosystem for topical delivery of therapeutics to inflamed intestinal mucosa following oral administration. Protamine nanocapsules with a new composition were for the first time...

04. January 2017

Abstract This research addresses the development and in vitro evaluation of a microparticulate system intended for intestine-targeted delivery of curcumin (CRM), a natural polyphenol with anti-inflammatory properties. Microspheres (Ms) based on zein (ZN) and Gantrez® AN119 (PVMMA) were prepared by spray-drying and coated with a pH-sensitive polymer (Eudragit® FS30D). An experimental design was performed to optimize the microparticulate formulation. A detailed characterization of systems was...

18. September 2016

Inflammatory bowel disease (IBD) is an idiopathic, relapsing disease involving chronic inflammation of the digestive tract, either in part or entire. IBD primarily includes Crohn’s disease (CD) and ulcerative colitis (UC) with a high prevalence rate in the industrialized world, with North America noting the highest frequency of people suffering with CD [1]. Incidence of IBD is from 31 to 71 per100,000 people for CD and 18-31 per 100,000 for UC and is increasing at an alarming rate. Although,...

24. November 2015

Two well-known active agents, Mesalamine (MES) and Sucralfate (SUC), were investigated for possible utilisation as fixed-dose combination product. The anti-inflammatory action of MES in association with bioadhesiveness and mucosal healing properties of SUC were considered promising for the development of a new compound containing both molecules, aimed as an improved treatment of ulcerative colitis. More